Dabuzalgron

CAS No. 219311-44-1

Dabuzalgron ( Ro 115-1240 )

Catalog No. M22674 CAS No. 219311-44-1

Dabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 113 In Stock
10MG 205 In Stock
25MG 333 In Stock
50MG 500 In Stock
100MG 718 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Dabuzalgron
  • Note
    Research use only, not for human use.
  • Brief Description
    Dabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM.
  • Description
    Dabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM. ERK1 / 2 activation helps Dabuzaron's cardioprotection. Dabuzaron (10 μM; 4 hours) protects NRVM from cell death caused by doxorubicin (DOX). Dabuzaren (10 μM; 4 hours) activation of α1A-AR alleviates the harmful effects of DOX on mitochondrial membrane potential and eliminates the activation of important elements of the apoptotic response to mitochondrial damage.Dabuzaron (10μg / kg; oral tube; twice daily; 7 consecutive days; C57B16J wild-type or α1A-AR gene knockout mice) treatment can prevent DOX cardiotoxicity by activating α1A-AR. Dabuzaron prevents mitochondrial function-related transcript reduction, up-regulates PGC1α, retains ATP content, and reduces oxidative stress in DOX-treated mouse hearts.
  • Synonyms
    Ro 115-1240
  • Pathway
    Angiogenesis
  • Target
    Adrenergic Receptor
  • Recptor
    α1A-adrenergic receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    219311-44-1
  • Formula Weight
    317.79
  • Molecular Formula
    C12H16ClN3O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:25 mg/mL(78.67 mM)
  • SMILES
    Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Beak J, et al. An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity. JACC Basic Transl Sci. 2017 Feb;2(1):39-53.
molnova catalog
related products
  • Bupranolol

    Bupranolol is an antagonist of β2-adrenergic receptor,and has been used for angina pectoris, hypertension, glaucoma, cardiac arrhythmia and as an antithrombotic.

  • Clenbuterol hydrochl...

    Clenbuterol hydrochloride is a β2 adrenergic receptor agonist. It is a powerful bronchodilator withfat burning properties.

  • Oxymetazoline hydroc...

    Oxymetazoline Hydrochloride is a selective alpha-1 agonist and partial alpha-2 agonist topical decongestant.Oxymetazoline is a selective alpha-1 agonist and partial alpha-2 agonist topical decongestant used in the form of Oxymetazoline hydrochloride.